Sorrento Therapeutics, Inc. – LSE:0L85.L
Sorrento Therapeutics stock price today
Sorrento Therapeutics stock price monthly change
Sorrento Therapeutics stock price quarterly change
Sorrento Therapeutics stock price yearly change
Sorrento Therapeutics key metrics
Market Cap | 661.53K |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -1.13 |
Revenue | 64.27M |
EBITDA | -344.57M |
Income | -534.2M |
Revenue Q/Q | 31.09% |
Revenue Y/Y | 16.88% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | -536.13% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeSorrento Therapeutics stock price history
Sorrento Therapeutics stock forecast
Sorrento Therapeutics financial statements
| Sep 2022 | 17.4M | -90.68M | -521.19% |
|---|---|---|---|
| Dec 2022 | 15.59M | -208.68M | -1338.24% |
| Mar 2023 | 16.25M | -139.61M | -859.12% |
| Jun 2023 | 15.02M | -95.21M | -633.69% |
| 2027 | 761.58M | 280.94M | 36.89% |
|---|
Analysts Price target
Financials & Ratios estimates
| Sep 2022 | 615614000 | 485.40M | 78.85% |
|---|---|---|---|
| Dec 2022 | 472840000 | 494.50M | 104.58% |
| Mar 2023 | 460063000 | 587.48M | 127.7% |
| Jun 2023 | 456692000 | 654.64M | 143.35% |
| Sep 2022 | -61.17M | -8.09M | 71.49M |
|---|---|---|---|
| Dec 2022 | -68.33M | -5.03M | 25.08M |
| Mar 2023 | -49.45M | 1.68M | 61.19M |
| Jun 2023 | -55.65M | -140K | 88.81M |
Sorrento Therapeutics alternative data
| Aug 2023 | 949 |
|---|---|
| Sep 2023 | 949 |
| Oct 2023 | 949 |
| Nov 2023 | 949 |
| Dec 2023 | 949 |
| Jan 2024 | 949 |
| Feb 2024 | 949 |
| Mar 2024 | 949 |
| Apr 2024 | 949 |
| May 2024 | 949 |
| Jun 2024 | 949 |
| Jul 2024 | 949 |
Sorrento Therapeutics other data
| Patent |
|---|
Application Filling date: 3 Mar 2022 Issue date: 11 Aug 2022 |
Application Filling date: 17 Dec 2021 Issue date: 4 Aug 2022 |
Application Filling date: 3 Apr 2020 Issue date: 16 Jun 2022 |
Application Filling date: 27 Feb 2020 Issue date: 2 Jun 2022 |
Application Filling date: 26 Jan 2022 Issue date: 12 May 2022 |
Grant Filling date: 3 Apr 2019 Issue date: 3 May 2022 |
Grant Filling date: 17 Apr 2017 Issue date: 26 Apr 2022 |
Grant Filling date: 18 Apr 2019 Issue date: 8 Mar 2022 |
Grant Filling date: 29 Jan 2019 Issue date: 15 Feb 2022 |
Application Filling date: 19 Oct 2021 Issue date: 10 Feb 2022 |
| Insider | Compensation |
|---|---|
Dr. Henry H. Ji (1964) Co-Founder, Chairman, Chief Executive Officer & Pres | $794,190 |
Dr. Hui Li Ph.D. Senior Vice President of ADC BU Leader | |
Mr. Bill Farley Vice President of Sales & Bus. Devel. | |
Dr. Michael A. Royal SVice President & Chief Medical Officer | |
Mr. Brian Cooley Senior Vice President of Lymphatic Systems BU Leader | |
Dr. Shawn Sahebi Ph.D. Senior Vice President of Strategy & Analytics | |
Dr. Alexis Nahama Senior Vice President & Head of RTX Program | |
| Mr. Najjam Asghar Senior Vice President & Chief Financial Officer | |
Dr. Mark R. Brunswick Senior Vice President of Regulatory Affairs | |
Mr. Brian Sun Senior Vice President, Gen. Counsel & Corporation Sec. |
-
What's the price of Sorrento Therapeutics stock today?
One share of Sorrento Therapeutics stock can currently be purchased for approximately $4.87.
-
When is Sorrento Therapeutics's next earnings date?
Unfortunately, Sorrento Therapeutics's (0L85.L) next earnings date is currently unknown.
-
Does Sorrento Therapeutics pay dividends?
No, Sorrento Therapeutics does not pay dividends.
-
How much money does Sorrento Therapeutics make?
Sorrento Therapeutics has a market capitalization of 661.53K and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 18.78% to 62.84M US dollars.
-
What is Sorrento Therapeutics's stock symbol?
Sorrento Therapeutics, Inc. is traded on the LSE under the ticker symbol "0L85.L".
-
What is Sorrento Therapeutics's primary industry?
Company operates in the Healthcare sector and Medical - Pharmaceuticals industry.
-
How do i buy shares of Sorrento Therapeutics?
Shares of Sorrento Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Sorrento Therapeutics's key executives?
Sorrento Therapeutics's management team includes the following people:
- Dr. Henry H. Ji Co-Founder, Chairman, Chief Executive Officer & Pres(age: 61, pay: $794,190)
- Dr. Hui Li Ph.D. Senior Vice President of ADC BU Leader
- Mr. Bill Farley Vice President of Sales & Bus. Devel.
- Dr. Michael A. Royal SVice President & Chief Medical Officer
- Mr. Brian Cooley Senior Vice President of Lymphatic Systems BU Leader
- Dr. Shawn Sahebi Ph.D. Senior Vice President of Strategy & Analytics
- Dr. Alexis Nahama Senior Vice President & Head of RTX Program
- Mr. Najjam Asghar Senior Vice President & Chief Financial Officer
- Dr. Mark R. Brunswick Senior Vice President of Regulatory Affairs
- Mr. Brian Sun Senior Vice President, Gen. Counsel & Corporation Sec.
-
Is Sorrento Therapeutics founder-led company?
Yes, Sorrento Therapeutics is a company led by its founder Dr. Henry H. Ji.
-
How many employees does Sorrento Therapeutics have?
As Jul 2024, Sorrento Therapeutics employs 949 workers.
-
When Sorrento Therapeutics went public?
Sorrento Therapeutics, Inc. is publicly traded company for more then 7 years since IPO on 29 Jan 2018.
-
What is Sorrento Therapeutics's official website?
The official website for Sorrento Therapeutics is sorrentotherapeutics.com.
-
Where are Sorrento Therapeutics's headquarters?
Sorrento Therapeutics is headquartered at 4955 Directors Place, San Diego, CA.
-
How can i contact Sorrento Therapeutics?
Sorrento Therapeutics's mailing address is 4955 Directors Place, San Diego, CA and company can be reached via phone at 858 203 4100.
Sorrento Therapeutics company profile:
Sorrento Therapeutics, Inc.
sorrentotherapeutics.comLSE
949
Medical - Pharmaceuticals
Healthcare
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 94 patients with COVID-19; Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California.
San Diego, CA 92121
:
ISIN: US83587F2020
:
